Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2025 06:45 ET | Source: Waldencast plc

Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update

Transformation efforts drive performance improvements at Obagi Medical with accelerating revenue Contrasted performance for Milk Makeup with Q2 2025 net revenue growth driven by U.S. channel...
November 16, 2025 01:02 ET | Source: Waldencast plc

Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting

NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new...
November 14, 2025 17:05 ET | Source: Waldencast plc

Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its...
November 12, 2025 07:33 ET | Source: Waldencast plc

Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates

LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, provided additional details for its upcoming earnings...
October 08, 2025 08:00 ET | Source: Waldencast plc

Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), the fastest growing professional skincare brand in the U.S. in 2024*, proudly unveils its latest innovation rooted in clinical...
September 10, 2025 06:45 ET | Source: Waldencast plc

Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand

LONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has...
August 18, 2025 17:43 ET | Source: Waldencast plc

Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation

Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand’s Addressable Market in the U.S. Milk Makeup Delivers Strong Retail Sales...
July 23, 2025 06:45 ET | Source: Waldencast plc

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

Acquisition strengthens Obagi Medical’s product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and...
May 13, 2025 16:15 ET | Source: Waldencast plc.

Waldencast Reports Q1 2025 Financial Results

Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4 million of Adjusted EBITDA LONDON, May 13, 2025 (GLOBE NEWSWIRE) --...
May 06, 2025 16:05 ET | Source: Waldencast plc.

Waldencast plc Announces First Quarter Fiscal 2025 Results Conference Call and Webcast

LONDON, May 06, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its First Quarter Fiscal 2025...